FDA Win Boosts Struggling Pharmaceutical Stock

NVO suffered its worst drop on record less than a month ago, but is pointed higher todayPharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the treatment of liver disease in the U.S. Today's pop comes just weeks after the company slashed its 2025 profit outlook and appointed a new CEO, resulting in a 21.8% bear gap on July 29, its worst drop on record. NVO is off 39% i ...